Table 1.
Baseline patient demographics and clinical characteristics
| Characteristic, n (%) | De novo patients (n = 327) |
Recurrent patients (n = 674) |
|---|---|---|
| Age at study enrollment | ||
| <50 years | 133 (40.7) | 246 (36.5) |
| 50–64 years | 132 (40.4) | 276 (40.9) |
| ≥65 years | 62 (19.0) | 152 (22.6) |
| Race | ||
| White | 251 (76.8) | 542 (80.4) |
| Black | 49 (15.0) | 77 (11.4) |
| Other | 27 (8.3) | 55 (8.2) |
| ECOG PS | ||
| 0–1 | 171 (52.3) | 284 (42.1) |
| ≥2 | 24 (7.3) | 36 (5.3) |
| Missing | 132 (40.4) | 354 (52.5) |
| Node status at initial diagnosis | ||
| Positive | 137 (41.9) | 378 (56.1) |
| Negative | 14 (4.3) | 196 (29.1) |
| Unknown | 176 (53.8) | 100 (14.8) |
| HR status at initial diagnosis | ||
| Positive | 180 (55.0) | 349 (51.8) |
| Negative | 136 (41.6) | 297 (44.1) |
| Unknown/missing | 11 (3.4) | 28 (4.2) |
| Number of metastatic disease sites | ||
| 1 | 114 (34.9) | 346 (51.3) |
| 2 | 99 (30.3) | 174 (25.8) |
| 3 | 58 (17.7) | 98 (14.5) |
| ≥4 | 56 (17.1) | 56 (8.3) |
| Site of metastatic disease | ||
| Bone | 181 (55.4) | 269 (39.9) |
| Liver | 154 (47.1) | 246 (36.5) |
| Lung | 88 (26.9) | 229 (34.0) |
| Lymph nodes | 111 (33.9) | 167 (24.8) |
| Breast | 93 (28.4) | 38 (5.6) |
| Mediastinum | 25 (7.6) | 54 (8.0) |
| Central nervous system | 17 (5.2) | 55 (8.2) |
| Pleural effusion | 19 (5.8) | 36 (5.3) |
| Other abdominal | 17 (5.2) | 29 (4.3) |
| Pelvis | 3 (0.9) | 13 (1.9) |
| Ascites | 2 (0.6) | 3 (0.4) |
| Other | 13 (4.0) | 19 (2.8) |
ECOG PS Eastern Cooperative Oncology Group performance status, HR hormone receptor